Data as of Apr 17
| -0.075 / -0.68%|
The 7 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 17.00, with a high estimate of 20.00 and a low estimate of 9.00. The median estimate represents a +54.97% increase from the last price of 10.97.
The current consensus among 8 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.